Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAD Phase Ib Study of Contraloid Acetate in Healthy Volunteers
NCT03955380Phase 1Completed
- Start
- Dec 2018
- Primary completion
- Apr 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of PRI-002 in Alzheimer's disease (AD) (4 arms). Primary endpoints: Assessment of safety and tolerability of Contraloid at 35 days, Area under curve (AUC) in plasma at 168 hours and 8 more. Started Dec 2018; status: completed.
02
Drugs
PRI-002
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT03955380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03955380.